NCT00004397已完成1 期
Phase I Study of Tin Mesoporphyrin in Patients on Long Term Heme Therapy for Prevention of Acute Attacks of Porphyria
National Center for Research Resources (NCRR)0 个研究点目标入组 20 人开始时间: 1998年1月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 20
研究概览
简要总结
OBJECTIVES: I. Evaluate the effectiveness of tin mesoporphyrin in reducing the number of heme infusions needed to prevent acute attacks of porphyria.
II. Evaluate the safety and tolerability of tin mesoporphyrin in these patients.
详细描述
PROTOCOL OUTLINE: This is an unblinded study. Patients start a preventive heme regimen and are followed for 6 months prior to tin mesoporphyrin. The frequency of attacks is recorded.
Patients receive tin mesoporphyrin once a week for 6 months. Patients must avoid sunlight during treatment and for 2 months thereafter. The frequency of heme infusions is reduced by half and the frequency of attacks of porphyria is monitored.
Patients are followed for 6 months after last treatment.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •PROTOCOL ENTRY CRITERIA:
- •-Disease Characteristics-- Documented acute intermittent porphyria, variegate porphyria, or hereditary coproporphyria causing 6 or more attacks per year Fewer than 2 attacks in the preceding 6 months if already on preventive heme therapy --Prior/Concurrent Therapy-- See Disease Characteristics --Patient Characteristics-- Performance status: Not specified Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Urinary porphobilinogen at least 20 mg/24 hours during acute symptoms Other: Not pregnant Fertile female patients must use effective contraception during and for 6 months prior to study No recurrent symptoms due to another illness No continuous (for longer than 1 month) symptoms of porphyria unless it is in addition to acute exacerbations No acute hemorrhagic disorder such as: Gastrointestinal bleeding Intracerebral hemorrhage No known hypersensitivity to tin mesoporphyrin No known hypersensitivity to any intravenous heme preparation No other condition which may increase risk to patient
排除标准
- 未提供
研究者
相似试验
已完成
1 期
Phase I Study of Heme Arginate With or Without Tin Mesoporphyrin in Patients With Acute Attacks of PorphyriaPorphyriaNCT00004398National Center for Research Resources (NCRR)24
已完成
2 期
Phase II Randomized Study of Tin Mesoporphyrin for Neonatal HyperbilirubinemiaGlucosephosphate Dehydrogenase DeficiencyHemolytic Disease of NewbornHyperbilirubinemiaNCT00004381Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
已完成
2 期
Studies in Porphyria III: Heme and Tin Mesoporphyrin in Acute PorphyriasPorphyriaNCT00004396National Center for Research Resources (NCRR)32
已完成
1 期
Phase I/II Study of Heme Arginate and Tin Mesoporphyrin for Acute PorphyriaPorphyriaNCT00004789National Center for Research Resources (NCRR)59
已完成
2 期
Phase II Study of Tin Mesoporphyrin vs Phototherapy for Hyperbilirubinemia in Premature NewbornsHyperbilirubinemiaNCT00004382Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)80